Table 2.

Neuroblastoma cell line panel genomics and clinical covariates.

Cell line	Clinical phenotypea	Patient gendera	Primary tumor site/cell origina	Stagea	TP53b	ALKb	MYCN b	Other mutation/Ampb
NB-SD	Relapse	M	Unk./BM	4	C176F	F1174L	Amp	ARID1A S1985fs*13
NB-EbC1	Relapse	M	Adrenal/adrenal	4	WT	WT	NA	KRAS G12D
SMS-SAN	Diagnosis	F	Adrenal/BM	4	WT	F1174L	Amp	—
NB-1643	Diagnosis	M	RP/RP	4	WT	R1275Q	Amp	—
LA-N-5	Diagnosis	M	Unk./BM	4	WT	R1275Q	Amp	—
CHP-134	Post-mortem	M	Adrenal/adrenal	4	WT	WT	Amp	—
NB69	Diagnosis	M	Adrenal/adrenal	3	WT	WT	NA	NTRK3 Q759K
NBL-S	Diagnosis	M	Adrenal/adrenal	3	WT	WT	NA	—
NGP	Post-treatment	M	Unk./lung	4	A159D C141W	WT	Amp	CDK4 Amp, MDM2 Amp
IMR-5c	Diagnosis	M	Abd./abd.	Unk.	WT	WT	Amp	ATM R189K
SK-N-AS	Relapse	F	Adrenal/BM	4	Nulld	WT	NA	NRAS Q61K

Abbreviations: Abd., abdomen; Amp, MYCN or other indicated gene amplified cell line; BM, bone marrow; F, female; LN, lymph node; M, male; NA, MYCN non-amplified cell line; RP, retroperitoneal; Unk., unknown; WT, wild-type.

^aAs previously described (58–61).

^bAs previously described (25, 26).

^cSubclone of IMR32, IMR32 clinical information shown.

^dDeletion of one TP53 allele and expression of C-terminally truncated TP53 variants from remaining TP53 allele due to a deletion in the intron 9/exon 10 junction, although SK-N-AS cells may maintain some partial TP53 functionality (9).